Brind.

Bharat Biotech International agrees to 40% price cut for malaria vaccine

18 reports, 3 independent Updated Fri 00:00
Mostly repetition Reached 15 outlets in its first 24 hours
Reports
18
Developments
2
Repetition
89%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Bharat Biotech International Limited announced an agreement with Gavi, the Vaccine Alliance, and UNICEF to supply the malaria vaccine RTS, S/AS01 at an equitable price. The vaccine, developed by GSK and manufactured by Bharat Biotech International as Mosqivac, will see its price cut by approximately 40%. The new price is set at EUR 5.50 per dose, expected to take effect by early 2027, and is projected to save child immunization programs around US$50 million between 2027 and 2029.

From newyorktelegraph.com

Why it matters

Some supportBrind's analysis of the reports

The agreement reflects sustained efforts to shape a more sustainable and competitive malaria vaccine market. The lower price is supported by $200 million invested by GSK and Bharat Biotech International in new manufacturing facilities and technology transfer to strengthen supply. This reduced cost is expected to help reach up to one million more children with the full four-dose course.

From newyorktelegraph.com

Who's involved

  • Bharat Biotech InternationalManufactures and supplies the vaccine under the brand name Mosqivac.
  • GAVIProvides financial backing for the agreement and vaccine procurement.
  • GSKDeveloped the malaria vaccine RTS, S/AS01.
  • UNICEFExecutes the agreement and manages vaccine procurement.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • GSKSpeculative

    GSK might see changes in the commercial viability and market pricing structure of the vaccine.

  • UNICEFSpeculative

    UNICEF could reduce procurement costs for global immunization programs.

  • NigeriaSpeculative

    Nigeria may improve the affordability and reach of national immunization programs due to lower vaccine costs.

How it developed

Newest first. Tap a step to see who reported it.
  1. BBIL supplies vaccines to Gavi at an equitable price.1 source
  2. BBIL is manufacturing a GSK vaccine and announced equitable pricing with Gavi.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
15 more outlets ran the same wire story